Montelukast plus cetirizine in the prophylactic treatment of seasonal allergic rhinitis: influence on clinical symptoms and nasal allergic inflammation
- 16 February 2004
- Vol. 59 (3) , 280-288
- https://doi.org/10.1046/j.1398-9995.2003.00416.x
Abstract
Background: The aim of our study was to investigate effects of 6‐week pretreatment of seasonal allergic rhinitis (AR) with cetirizine, and montelukast, alone and in combination. Antihistamine/antileukotriene treatment is effective in AR. Antihistamines may prevent AR symptoms while prophylactic activity of antileukotrienes remains unclear.Methods: Sixty AR patients, aged 18–35 years, were randomized to receive placebo, montelukast only, cetirizine only, or montelukast plus cetirizine, 6 weeks prior and 6 weeks after the beginning of grass pollen season. Mean self‐recorded in‐season symptom scores and mean weekly all‐symptom scores were analyzed. In 31 patients, nasal lavages were performed before treatment, and at the end of the study, i.e. 12 weeks after the treatment initiation. Eosinophil and basophil counts, eosinophil cationic protein (ECP), and mast cell tryptase (MCT) levels were evaluated in lavage samples.Results: Combined montelukast/cetirizine pretreatment significantly reduced in‐season symptom score for sneezing, eye itching, nasal itching, rhinorrhea, and congestion. Montelukast plus cetirizine were more effective than cetirizine alone in preventing eye itching, rhinorrhea, and nasal itching. Moreover, combined pretreatment with montelukast and cetirizine delayed appearance of AR symptoms. Eosinophil nasal lavage fluid counts were significantly increased during pollen season in placebo and montelukast‐only groups. No differences were observed in basophil counts. The in‐season ECP level was significantly increased in all groups except montelukast‐plus‐cetirizine group. In‐season MCT levels were not increased.Conclusion: Combined antihistamine and antileukotriene treatment started 6 weeks before the pollen season is effective in preventing AR symptoms and reduces allergic inflammation in nasal mucosa during natural allergen exposure.Keywords
This publication has 33 references indexed in Scilit:
- Inflammatory mediators in naturally occurring rhinitisClinical and Experimental Allergy, 1998
- Mediators of nasal blockage in allergic rbtisAllergy, 1997
- Monitoring nasal allergic inflammation by measuring the concentration of eosinophil cationic protein and eosinophils in nasal secretionsAllergy, 1995
- Correlations between Complaints, Inflammatory Cells and Mediator Concentrations in Nasal Secretions after Nasal Allergen Challenge and during Natural Allergen ExposureInternational Archives of Allergy and Immunology, 1995
- Proinflammatory cytokines in nasal secretions of allergic subjects after antigen challenge.American Journal of Respiratory and Critical Care Medicine, 1994
- Indirect evidence of nasal inflammation assessed by titration of inflammatory mediators and enumeration of cells in nasal secretions of patients with chronic rhinitisJournal of Allergy and Clinical Immunology, 1992
- Mast cells and eosinophils in the allergic mucosal response to allergen challenge: Changes in distribution and signs of activation in relation to symptomsJournal of Allergy and Clinical Immunology, 1992
- Immunohistology of the nasal mucosa in seasonal allergic rhinitis: Increases in activated eosinophils and epithelial mast cellsJournal of Allergy and Clinical Immunology, 1992
- Langerhans Cells in Nasal Mucosa of Patients with Grass Pollen AllergyImmunobiology, 1991
- The formation of eosinophil and neutrophil chemotactic activity during a pollen season and after allergen challengeJournal of Allergy and Clinical Immunology, 1989